Objective: Venous thromboembolism (VTE) is reported to occur in up to 33% of patients undergoing major vascular surgery. Despite this high incidence, patients inconsistently receive timely VTE chemoprophylaxis. The true incidence of VTE among patients receiving delayed VTE chemoprophylaxis is unknown. We sought to identify the association of VTE chemoprophylaxis timing on VTE risk, postoperative transfusion rates, and 30-day mortality and morbidity in patients undergoing major open vascular surgery. The VTE rate was compared between patients receiving early versus delayed VTE chemoprophylaxis. VTE chemoprophylaxis delay was defined as therapy initiation more than 24 hours after surgery. The risk-adjusted association of the chemoprophylaxis timing and VTE development was determined using multivariable logistic regression. Blood transfusion rates, 30-day mortality, and postoperative complications were compared across groups.
Results: A total of 2421 patients underwent major open vascular surgery, including 196 oAAA repair, 259 aortofemoral bypass, and 1966 LEB. The overall incidence of 30-day VTE was 1.40%, ranging from 1.12% for LEB to 3.57% for oAAA repair. Among patients receiving early VTE chemoprophylaxis, the rate of VTE was 0.78% versus 2.26% among those with a delay in VTE chemoprophylaxis (P ¼ .002). When accounting for the preoperative risk of VTE, delayed chemoprophylaxis was associated with a significantly higher risk of VTE (odds ratio, 2.38; 95% confidence interval, 1.12-5.06; P ¼ .024). The early VTE chemoprophylaxis group was associated with a significantly decreased risk of bleeding compared with those with a delay (14.31% vs 18.90%; P ¼ .002). Overall 30-day mortality and postoperative complications were similar with the exception of an associated higher rate of infectious complications in the delayed VTE chemoprophylaxis group, including superficial surgical site infection (6.00% vs 4.06%; P ¼ .028), pneumonia (3.25% vs 1.85%; P ¼ .028), urinary tract infection (2.95% vs 1.57%; P ¼ .020), and severe sepsis (3.05% vs 1.71%; P ¼ .029).
Conclusions: Although patients undergoing major open vascular surgery have a low risk of VTE at baseline, there is a significantly greater risk of developing VTE among patients who have a delay in the administration of VTE chemoprophylaxis. Postoperative transfusion rates were significantly lower among patients receiving early chemoprophylaxis. There were no differences in the 30-day mortality and postoperative complications, except for infectious complications. Given these findings, surgeons should consider early chemoprophylaxis in the postoperative setting after major open vascular surgery without contraindication. (J Vasc Surg 2018; 67:262-71.) Venous thromboembolism (VTE) is a common and potentially preventable surgical complication with high morbidity. Although the association between VTE and nonvascular surgical procedures is well-established, 1 less is known about VTE after major vascular surgery.
The reported incidence of deep venous thrombosis (DVT) after elective open abdominal aortic aneurysm (oAAA) repair and lower extremity infrainguinal bypass (LEB) varies from 0% to 33% [2] [3] [4] [5] [6] [7] [8] [9] [10] in those who do not receive postoperative pharmacologic prophylaxis to 2% to 9% in those who do. 3, 5, [11] [12] [13] [14] The variable reported VTE rate is underscored by inconsistencies in these studies, including the variation in the type, timing, and anticoagulation dose administered, different techniques used to diagnose DVT, and inconsistent below-knee DVT inclusion. Moreover, complications resulting from DVTs, including pulmonary embolism (PE), are not well-described. The typical vascular surgery patient has multiple risk factors that predispose him or her to VTE, including advanced age, prolonged immobility, and iatrogenic intimal vascular injury. The Caprini Risk Assessment Model has been used to estimate postoperative VTE risk in a large surgical cohort of patients that encompassed a myriad of general and surgical subspecialties. [15] [16] [17] However, no vascular surgery-specific risk assessment tool exists. In high-risk patient populations, defined as a Caprini score of five or greater, the American College of Chest Physicians guidelines recommend that VTE chemoprophylaxis with low-molecular-weight heparin (LMWH) or low-dose unfractionated heparin be administered in the absence of contraindications (grade 1B evidence). 18 In regard to major vascular surgery, the available VTE prophylaxis guidelines are limited in number and specificity, [19] [20] [21] [22] and surveys of vascular surgeons show wide discrepancies in the postoperative chemoprophylaxis use. 18, [23] [24] [25] These discrepancies exist not only for the use of chemoprophylaxis, but for the timing of use as well. This may in part be explained by two important factors: the near universal intravenous intraoperative use of heparin and the potential postoperative bleeding risk with a new vascular anastomosis. Given the variation in reported VTE incidence after major vascular surgery and in postoperative VTE prophylaxis timing, we sought to (1) determine the VTE incidence after oAAA repair, aortobifemoral bypass (AFB), and LEB among a statewide quality collaborative, (2) examine the relationship between early versus delayed postoperative VTE chemoprophylaxis and VTE events, and (3) determine if there is a difference in blood transfusion rates and 30-day complications for patients receiving early versus delayed VTE chemoprophylaxis. We hypothesized that VTE rates would increase with delay in chemoprophylaxis and overall bleeding rates would be low.
METHODS
Data source. The Michigan Surgical Quality Collaborative (MSQC) is a statewide hospital collaborative dedicated to overall surgical quality improvement. Currently MSQC includes 73 participating hospitals. The collaborative captures data on 306 different Current Procedural Terminology (CPT) codes arranged into 14 broadly defined procedure groups including general surgery, vascular surgery, and hysterectomy procedures. MSQC data are abstracted in a hybrid approach by trained Surgical Clinical Quality Reviewers (SCQRs). The hybrid approach includes the SCQR providing the full list of eligible cases from which a sample is to be drawn. These cases are then stratified into procedural groups followed by simple random sampling to select the cases for data abstraction. The data abstraction process is then performed by the SCQR. The SCQR performs a comprehensive chart review for the specific data points in the data dictionary. This process includes review of preoperative history and physical, operative reports, postoperative progress notes, laboratory results, radiologic studies and reports, and discharge summaries. In regard to specific variables that are important in our study (ie, VTE chemoprophylaxis, type, and timing), SCQR record the initial start time and date of administration by chart review. For complete information on MSQC, data sampling and abstraction procedures please see www.msqc.org. The use of MSQC data was granted through a standard institutional review board approval and a data user agreement through the MSQC compliance office. All patient information was deidentified and did not require informed consent. were included in the analysis. CPT codes were used to select these operations (Supplemental Table I , online only). Urgent, emergent, and elective cases were included. The following procedures were excluded: endovascular abdominal aortic aneurysm repair, ruptured abdominal aortic aneurysm repair, extraanatomic bypass (ie, axillary to femoral bypass), and mesenteric bypasses. We also excluded 1 patient for incomplete data, 168 patients who had a documented contraindication to anticoagulation, and 24 patients who died the day of the procedure and thus did not have the opportunity to develop a VTE event. Finally, we excluded 871 patients who did not receive VTE chemoprophylaxis, because our main question was timing of VTE chemoprophylaxis. This resulted in 2421 patients who underwent major open vascular surgeries and received VTE chemoprophlaxis at some time during the postoperative period. We then separated the procedures into two groups, those who had no delay in VTE chemoprophylaxis (58.0%), which we defined as administration of chemoprophylaxis within 24 hours of the operation, and those who had a delay in VTE chemoprophylaxis (42.0%), which we defined as administration more than 24 hours after the operation. Outcomes. The primary outcome was VTE (DVT and/or PE) after any major open vascular surgery. Secondary outcomes included rate of blood transfusion, 30-day mortality, and postoperative complications including surgical site infection (SSI), pneumonia, acute renal insufficiency, urinary tract infection (UTI), stroke or cerebrovascular accident, postoperative cardiac arrest, intraoperative or postoperative myocardial infarction, sepsis, severe sepsis, and Clostridium difficile or central-line associated bloodstream infections.
ARTICLE HIGHLIGHTS
DVT was defined as the identification of a new blood clot or thrombus within the deep venous system (ulnar, radial, brachial, subclavian, axillary, internal jugular, vena cava, portal vein, iliac, deep femoral, popliteal, and tibial veins), which may be coupled with inflammation identified within 30 days of the operation. The diagnosis of DVT was confirmed by duplex ultrasound, venogram, or computed tomography scan. A diagnosis of PE was determined by ventilation perfusion scan (interpreted as high probability of PE), positive computed tomography angiogram, transesophageal echocardiogram, pulmonary arteriogram, or two-dimensional transthoracic echocardiogram. A blood transfusion was defined as any transfusion of packed or whole red blood cells up to and including 72 hours after the surgery end time. Fresh frozen plasma and platelets were excluded. and characteristics were compared between patients receiving early versus delayed VTE chemoprophylaxis using univariate analysis. Next, the primary outcome was assessed in a univariate analysis, examining the association of VTE chemoprophylaxis delay with postoperative DVT, PE, and overall VTE. Using a stepwise logistic regression model to adjust for patient preoperative risk factors, and surgery type, including all significant variables with P < .10, a multivariable logistic regression model was performed. These variables included smoking status, history of DVT, congestive heart failure, and urgency of procedure (Table I) . Based on known risk factors for VTE, we also included American Society of Anesthesiologists class, diabetes, dyspnea, functional status, hypertension, cancer, bleeding disorder, and operation duration. The association of delay of chemoprophylaxis with VTE was then assessed using multivariable logistic regression. A multivariable analysis was then performed, adjusting for all significant preoperative factors, and intraoperative factors, to assess the association of VTE chemoprophylaxis delay on risk of bleeding (as defined by need for postoperative transfusion). Univariate statistics were used to examine the association of delay of chemoprophylaxis with complications and mortality. A power calculation for measuring a significant difference in VTE rate when adjusting for delay of Table I . Patient demographics were similar between both groups with the exception of nonsmokers being more common in the group receiving early VTE chemoprophylaxis (45.41% vs 41.04%; P ¼.033), and congestive heart failure being more frequent (2.66% vs 1.00%; P ¼ .002) in the delayed VTE chemoprophylaxis group. Of note, there was no difference in the Charlson index between the two groups (9.26 6 1.39 vs 9.26 6 1.45; P ¼ .841). There were a higher percentage of elective cases in the early VTE chemoprophylaxis group (70.96% vs 60.93%; P < .001) compared with the delayed group. Additionally, the delayed VTE chemoprophylaxis group had a higher percentage of emergent (8.86% vs 4.84%; P < .001) and urgent (30.22% vs 24.20%; P ¼ .001). The majority of patients received subcutaneous heparin three times a day or intravenous heparin (n ¼ 1138; 47%) for VTE chemoprophylaxis during their postoperative stay compared with the less frequent choice of subcutaneous heparin two times a day (n ¼ 480; 19.82%), LMWH (n ¼ 438; 18.09%), or other anticoagulation (n ¼ 205; 8.47%). A minority of patients (n ¼ 160; 6.61%) had a combination of VTE chemoprophylaxis during their hospitalization (ie, heparin three times a day changing to LMWH later in the hospitalization [Supplemental Table II, online only]). In addition, patients receiving early VTE chemoprophylaxis had a higher percentage of patients on heparin two or three times a day or intravenously compared with the delayed group who had a higher percentage of patients on LMWH, other anticoagulation, or combination therapy.
Timing of chemoprophylaxis administration and its association with VTE. VTE (PE and DVT) rates in patients receiving early VTE chemoprophylaxis compared with patients receiving delayed VTE chemoprophylaxis overall and by surgery type are described in Table II . Among patients receiving some type of postoperative chemoprophylaxis, the overall incidence of VTE was 1.40% (n ¼ 34). VTE occurred in 3.57% of patients undergoing oAAA, 1.93% of patients undergoing AFB, and 1.12% of patients undergoing LEB (Table II) . Of the 34 VTE events, 30 were DVTs without evidence of concurrent PE, 3 were PEs without evidence of concurrent DVTs, and 1 was a combined DVT and PE. The comparison between early versus delayed VTE chemoprophylaxis administration is also described in Table II . There was a statistically higher VTE rate in patients who received delayed chemoprophylaxis compared with those who had no delay (2.26 vs 0.78%; P ¼ .002). This difference remained significant in our multivariable model when accounting for patientspecific preoperative risk of VTE, with a significantly higher odds of VTE associated with chemoprophylaxis delay greater than 24 hours (odds ratio, 2.38; 95% confidence interval , 1.12-5.06; P ¼ .024; Table III ). The associated rate of VTE was higher among patients receiving delayed VTE chemoprophylaxis undergoing all three operations compared with early administration; however, this only achieved statistical significance among patients undergoing LEB (odds ratio, 3.05; 95% confidence interval, 1.21-7.72; P ¼ .018) when looking at the operative breakdown of oAAA, AFB and LEB in Table III .
Secondary outcomes. The postoperative blood transfusion rate among patients with early VTE chemoprophylaxis compared with delayed VTE chemoprophylaxis overall and by each surgery is described in Table IV . The overall transfusion rates ranged from 15.44% for AFB to 20.92% for oAAA (Table IV) . There was a statistically decreased postoperative transfusion risk (bleeding risk) among patients receiving early routine chemoprophylaxis compared those who received a delay (14.31% vs 18.90%; P ¼ .002), even after accounting for intraoperative blood loss and intraoperative transfusions. When taking a closer look at the specific operations separately, we found no difference in postoperative blood transfusions when looking at each oAAA and AFB (oAAA, P ¼ .919; AFB, P ¼ .195); however, LEB was associated with a higher postoperative blood transfusion in the delayed VTE chemoprophylaxis group (18.78% vs 13.92%; P ¼ .004). Table V summarizes the non-VTE-related complications and mortality in patients receiving early VTE chemoprophylaxis compared with patients receiving delayed VTE chemoprophylaxis. Overall mortality, excluding patients with contraindications to VTE prophylaxis, was 3.11% (n ¼ 75). In addition to postoperative transfusion, the most common 30-day complications were superficial SSI (4.87%; n ¼ 118), acute renal insufficiency (3.39%; n ¼ 82), and pneumonia (2.44%; n ¼ 59). Overall 30-day mortality and postoperative complications were similar between both groups with the exception of a higher rate of superficial SSI (6.00% vs 4.06%; P ¼ .028), pneumonia (3.25% vs 1.85%; P ¼ .028), UTI (2.95% vs 1.57%; P ¼ .020), and severe sepsis (3.05% vs 1.71%; P ¼ .029) in the group with delayed VTE chemoprophylaxis. The VTE rate in patients who suffered from these postoperative complications was low overall, with the exception of pneumonia, which was 6.78% (n ¼ 4). Of the four patients who had a VTE and pneumonia, one had received early VTE chemoprophylaxis and three had received delayed VTE chemoprophylaxis.
DISCUSSION
This study confirms that the overall VTE rate is relatively low, ranging from 1.12% among patients undergoing LEB to 3.57% among patients undergoing open AAA repair. However, higher VTE rates are associated with a delay in chemoprophylaxis (odds ratio, 2.38; 95% confidence interval, 1.12-5.06; P ¼ .024). There was a statistically decreased postoperative transfusion risk (bleeding risk) among patients receiving early routine chemoprophylaxis compared with those who received a delay (14.31% vs 18.90%; P ¼ .002), even after accounting for intraoperative blood loss and intraoperative transfusions. The overall 30-day mortality and morbidity were no different with the exception of infectious complications, including superficial SSI, pneumonia, UTI, and severe sepsis. VTE after major vascular surgery seems to be lower than previously reported in the literature. However, most studies have defined postoperative VTE using routine screening in the postoperative setting. VTE events reported in MSQC tend to be identified based on clinical significance, rather than routine venous duplex Unfortunately, given the retrospective nature of this statewide dataset, we are unable to know the specific reason behind delaying chemoprophylaxis other than if patients met contraindication criteria. It is unclear whether or not the decision for VTE chemoprophylaxis is facility driven or surgeon specific; however, moving forward this would be interesting to investigate.
Prior studies fail to investigate VTE chemoprophylaxis timing after major open vascular surgery. We found that there was a significant increase in the associated VTE rate when prophylaxis was delayed more than 24 hours postoperatively. 17, 26 A potential reason for delaying immediate VTE chemoprophylaxis postoperatively may be the fear of bleeding. This concern for bleeding may explain the observation that among LEB patients with delayed chemoprophylaxis, there was a higher rate of transfusion. This could potentially be explained by an unmeasured bleeding risk that motivated the delay in chemoprophylaxis. However, only 168 patients were documented as having a contraindication to chemoprophylaxis because of active bleeding, allergy, or history of heparin-induced thrombocytopenia. Based on the available data, the remaining patients had no documented reason for delay. Despite this observed increase in bleeding among delayed chemoprophylaxis, there was a lower risk of bleeding among patients receiving early chemopropylaxis. This finding suggests that it may be safe to consider early chemoprophylaxis, even among patients undergoing open abdominal procedures. We also found no difference in overall postoperative complications with the exception of infectious complications, including superficial SSI, pneumonia, UTI, and severe sepsis. Delayed chemoprophylaxis was associated with a higher risk of all four infectious complications. When examining these complications, 6.78% of patients with pneumonia had a concurrent VTE. Previous population and registry studies have identified a link between pneumonia and VTE. [27] [28] [29] [30] This may be due in part to inflammatory and/or infectious stimuli effect on the venous endothelium or simply a reflection of these patients immobility and frailty. Scarborough et al 28 identified VTE events in conjunction with the timing of postoperative complications and found that 5.6% of patients who developed pneumonia subsequently developed a VTE. Our findings would suggest an even higher percentage of patients with VTE and pneumonia. These results, within the context of these previous studies, echo the importance of VTE chemoprophylaxis, especially in this subset of patients. Although there is an association between infectious complications and delayed chemoprophylaxis, the timing of these complications is unclear.
Patients who are at highest risk of infection may be the same patients who are not receiving chemoprophylaxis owing to a fear of bleeding complications. Last, it is important to note that there was still a small group of patients that despite timely, appropriate VTE chemoprophylaxis, that still developed a VTE event postoperatively (Table III) . This relates to the concept of breakthrough VTE. A better understanding of the mechanisms of breakthrough VTE requires patient specific data not available through existing registries.
Limitations. Our study has several key limitations. First, the data collection is retrospective and there are limited data regarding the complexity of cases. Furthermore, a major limitation secondary to the data use agreement, we do not have hospital identifiers for us to analyze the data on a hospital level. This information would be helpful, because it would allow us to identify potential unmeasured confounders related to hospital-specific practices and case mix. Using the MSQC dataset, we were only able to account for operating time, estimated blood loss, and the need for intraoperative transfusions. Additionally, human error with database entry leaves a potential for inaccuracy and/or missing data; however, this was small overall. The MSQC has robust mechanisms to mitigate the chance of erroneous data. Data are internally audited and regularly validated. Another key limitation of the MSQC dataset for this study is the fact that the data abstracters only record postoperative blood transfusion up to 72 hours postoperatively. This limitation becomes important if patients develop bleeding more than 72 hours after the index operation. Additionally, a limitation in using the MSQC dataset is that, although we can identify whether or not a complication was present, it is impossible to extrapolate when it occurred in relation to the VTE event. Thus, we are unable to draw conclusions about the association between VTE and postoperative complications. Finally, we describe the rate of symptomatic VTE. The true incidence of DVT and/or PE is not known. Most centers do not routinely screen for VTE and this currently is not recommended; however, we feel our data reflect real-world practice. This realistic view of the care of vascular patients provides ample evidence of variation in the use of VTE chemoprophylaxis and outcomes.
In summary, although patients undergoing major open vascular surgery have a relatively low risk of VTE at baseline, delay of chemoprophylaxis beyond 24 hours is associated with higher risk of VTE when compared with early chemoprophylaxis. Early chemoprophylaxis was not associated with a higher rate of blood transfusion.
In contrast, we found a significantly lower rate of bleeding in the patients who received early VTE chemoprophylaxis. Given these findings, we encourage providers to consider VTE chemoprophylaxis in the early postoperative setting after routine major vascular surgery because it seems to be safe and associated with lower rates of postoperative VTE when compared with delaying VTE chemoprophylaxis beyond 24 hours. Combination therapy includes any combination of VTE chemoprophylaxis during the hospital stay (ie, heparin three times a day changing to LMWH later in the hospitalization).
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